AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity

Xuanming Chen1,2,*, Cheng Shen3,*, Zhe Wei2, Rui Zhang2, Yongsheng Wang4, Lili Jiang5, Ke Chen2, Shuang Qiu2, Yuanli Zhang2, Ting Zhang2,6, Bin Chen7, Yanjun Xu2, Qiyi Feng1,2, Jinxing Huang1,2, Zhihui Zhong2,6, Hongxia Li1, Guowei Che3 ( ), Kai Xiao1,2 ( )
National Chengdu Center for Safety Evaluation of Drugs and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610000, China
Sichuan Kangcheng Biotechnology Co., Ltd. Chengdu 610000, China
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610000, China
GCP Center, West China Hospital, Sichuan University, Chengdu 610000, China
Department of Pathology, West China Hospital, Sichuan University, Chengdu 610000, China
Laboratory of Nonhuman Primate Disease Modeling Research, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610000, China
Center for Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610000, China

*These authors contributed equally to this work.

Show Author Information

Abstract

Objective

Patient-derived xenograft (PDX) models have shown great promise in preclinical and translational applications, but their consistency with primary tumors in phenotypic, genetic, and pharmacodynamic heterogeneity has not been well-studied. This study aimed to establish a PDX repository for non-small cell lung cancer (NSCLC) and to further elucidate whether it could preserve the heterogeneity within and between tumors in patients.

Methods

A total of 75 surgically resected NSCLC specimens were implanted into immunodeficient NOD/SCID mice. Based on the successful establishment of the NSCLC PDX model, we compared the expressions of vimentin, Ki67, EGFR, and PD-L1 proteins between cancer tissues and PDX models using hematoxylin and eosin staining and immunohistochemical staining. In addition, we detected whole gene expression profiling between primary tumors and PDX generations. We also performed whole exome sequencing (WES) analysis in 17 first generation xenografts to further assess whether PDXs retained the patient heterogeneities. Finally, paclitaxel, cisplatin, doxorubicin, atezolizumab, afatininb, and AZD4547 were used to evaluate the responses of PDX models to the standard-of-care agents.

Results

A large collection of serially transplantable PDX models for NSCLC were successfully developed. The histology and pathological immunohistochemistry of PDX xenografts were consistent with the patients’ tumor samples. WES and RNA-seq further confirmed that PDX accurately replicated the molecular heterogeneities of primary tumors. Similar to clinical patients, PDX models responded differentially to the standard-of-care treatment, including chemo-, targeted- and immuno-therapeutics.

Conclusions

Our established PDX models of NSCLC faithfully reproduced the molecular, histopathological, and therapeutic characteristics, as well as the corresponding tumor heterogeneities, which provides a clinically relevant platform for drug screening, biomarker discovery, and translational research.

Electronic Supplementary Material

Download File(s)
cbm-18-1-184_ESM.pdf (149.5 KB)

References

【1】
【1】
 
 
Cancer Biology & Medicine
Pages 184-198

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Chen X, Shen C, Wei Z, et al. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity. Cancer Biology & Medicine, 2021, 18(1): 184-198. https://doi.org/10.20892/j.issn.2095-3941.2020.0012

669

Views

42

Downloads

31

Crossref

29

Web of Science

33

Scopus

Received: 11 January 2020
Accepted: 28 June 2020
Published: 01 February 2021
©2021 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License